Urinary Incontinence - Market Insights, Epidemiology and Market Forecast -2023-7MM
This report can be delivered to the clients within 24 Hours
DelveInsight’s “Urinary Incontinence - Market Insights, Epidemiology and Market Forecast-2023-7MM” Reports provides an overview of the disease and global market size of the Urinary Incontinence for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Urinary Incontinence from 2013-2023.
Urinary Incontinence is a multifactorial syndrome which occurs due to the failure of the storage function of the lower urinary tract and loss of bladder control resulting in leakage of urine. Embarrassment, isolation, and depression are observed among patients with Urinary Incontinence. Millions of individuals worldwide are suffering from Urinary Incontinence. It is most common among the old people. It increases the chances of developing several medical conditions such as local skin irritation, rashes, and urinary infections.
According to DelveInsight, the market size for Urinary Incontinence of 7 MM is estimated to be USD XX Million by 2023 at a CAGR of 9.5% for the forecast period i.e., 2013-2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
SCOPE
The report will help in developing business strategies by understanding the trends shaping and driving the Urinary Incontinence market.
Organize sales and marketing efforts by identifying the best opportunities for Urinary Incontinence in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
To understand the future market competition in the 7MM market of Urinary Incontinence and Insightful review of the key market drivers and barriers.
To understand the regulatory scenario in major markets.
The Report also covers the detailed historical and forecasted Urinary Incontinence market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.
DelveInsight’s “Urinary Incontinence - Market Insights, Epidemiology and Market Forecast-2023-7MM” Reports provides an overview of the disease and global market size of the Urinary Incontinence for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Urinary Incontinence from 2013-2023.
Urinary Incontinence is a multifactorial syndrome which occurs due to the failure of the storage function of the lower urinary tract and loss of bladder control resulting in leakage of urine. Embarrassment, isolation, and depression are observed among patients with Urinary Incontinence. Millions of individuals worldwide are suffering from Urinary Incontinence. It is most common among the old people. It increases the chances of developing several medical conditions such as local skin irritation, rashes, and urinary infections.
According to DelveInsight, the market size for Urinary Incontinence of 7 MM is estimated to be USD XX Million by 2023 at a CAGR of 9.5% for the forecast period i.e., 2013-2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
SCOPE
The report will help in developing business strategies by understanding the trends shaping and driving the Urinary Incontinence market.
Organize sales and marketing efforts by identifying the best opportunities for Urinary Incontinence in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
To understand the future market competition in the 7MM market of Urinary Incontinence and Insightful review of the key market drivers and barriers.
To understand the regulatory scenario in major markets.
The Report also covers the detailed historical and forecasted Urinary Incontinence market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.
Report Introduction
Urinary Incontinence Market Overview at a Glance
7 MM MARKET SIZE OF URINARY INCONTINENCE (2013-2023)
Total Market Share Distribution of Urinary Incontinence for 7 MM in 2016
Total Market Share Distribution of Urinary Incontinence for 7 MM in 2023
Urinary Incontinence
Overview
Pathophysiology
Etiology
Risk factors
Diagnosis
Treatment
Epidemiology and Patient Population
Total number of Prevalent cases – 7MM Countries – (2016 & 2023)
Secondary Studies referred
United States
Prevalent Cases of Urinary Incontinence in United States
Percentage Distribution ofUrinary Incontinence by Sub Types
Germany
Prevalent Cases of Urinary Incontinence in Germany
Percentage Distribution ofUrinary Incontinence by Sub Types
France
Prevalent Cases of Urinary Incontinence in France
Percentage Distribution ofUrinary Incontinence by Sub Types
United Kingdom
Prevalent Cases of Urinary Incontinence in United Kingdom
Percentage Distribution ofUrinary Incontinence by Sub Types
Spain
Prevalent Cases of Urinary Incontinence in Spain
Percentage Distribution ofUrinary Incontinence by Sub Types
Italy
Prevalent Cases of Urinary Incontinence in Italy
Percentage Distribution ofUrinary Incontinence by Sub Types
Japan
Prevalent Cases of Urinary Incontinence in Japan
Percentage Distribution ofUrinary Incontinence by Sub Types
Treatment Algorithm
Current Unmet Needs
Marketed Drugs
Major Marketed Drugs
Myrbetriq BetmigaBetani
Description
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Efficacy
Safety
Side effects
Botox
Description
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Efficacy
Safety
Side effects
Toviaz
Description
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Efficacy
Safety
Side effects
VESIcare
Description
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Efficacy
Safety
Side effects
Emerging Therapies
Key Emerging Therapies
Vibegron: Kissei Pharmaceutical Co., Ltd.
Product Development Activities
Clinical Development
Product Profile
Clinical Trial by Phase
AbobotulinumtoxinA: Ipsen Group
Clinical Development
Product Profile
Clinical Trial by Phase
Mirabegron+Solifenacin: Astellas Pharma Inc.
Product Development Activities
Clinical Development
Product Profile
Clinical Trial by Phase
Global Urinary Incontinence: Country-Wise Market Analysis
Overview on Total Urinary Incontinence Market (2016)
Overview on Total Urinary Incontinence Market (2023)
Global Urinary incontinence: Market Analysis
United States Market Size
Europe Market Size
Germany Market Size
France Market Size
United Kingdom Market Size
Spain Market Size
Italy Market Size
Japan Market Size
Market Drivers
Market Barriers
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
Urinary Incontinence Market Overview at a Glance
7 MM MARKET SIZE OF URINARY INCONTINENCE (2013-2023)
Total Market Share Distribution of Urinary Incontinence for 7 MM in 2016
Total Market Share Distribution of Urinary Incontinence for 7 MM in 2023
Urinary Incontinence
Overview
Pathophysiology
Etiology
Risk factors
Diagnosis
Treatment
Epidemiology and Patient Population
Total number of Prevalent cases – 7MM Countries – (2016 & 2023)
Secondary Studies referred
United States
Prevalent Cases of Urinary Incontinence in United States
Percentage Distribution ofUrinary Incontinence by Sub Types
Germany
Prevalent Cases of Urinary Incontinence in Germany
Percentage Distribution ofUrinary Incontinence by Sub Types
France
Prevalent Cases of Urinary Incontinence in France
Percentage Distribution ofUrinary Incontinence by Sub Types
United Kingdom
Prevalent Cases of Urinary Incontinence in United Kingdom
Percentage Distribution ofUrinary Incontinence by Sub Types
Spain
Prevalent Cases of Urinary Incontinence in Spain
Percentage Distribution ofUrinary Incontinence by Sub Types
Italy
Prevalent Cases of Urinary Incontinence in Italy
Percentage Distribution ofUrinary Incontinence by Sub Types
Japan
Prevalent Cases of Urinary Incontinence in Japan
Percentage Distribution ofUrinary Incontinence by Sub Types
Treatment Algorithm
Current Unmet Needs
Marketed Drugs
Major Marketed Drugs
Myrbetriq BetmigaBetani
Description
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Efficacy
Safety
Side effects
Botox
Description
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Efficacy
Safety
Side effects
Toviaz
Description
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Efficacy
Safety
Side effects
VESIcare
Description
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Efficacy
Safety
Side effects
Emerging Therapies
Key Emerging Therapies
Vibegron: Kissei Pharmaceutical Co., Ltd.
Product Development Activities
Clinical Development
Product Profile
Clinical Trial by Phase
AbobotulinumtoxinA: Ipsen Group
Clinical Development
Product Profile
Clinical Trial by Phase
Mirabegron+Solifenacin: Astellas Pharma Inc.
Product Development Activities
Clinical Development
Product Profile
Clinical Trial by Phase
Global Urinary Incontinence: Country-Wise Market Analysis
Overview on Total Urinary Incontinence Market (2016)
Overview on Total Urinary Incontinence Market (2023)
Global Urinary incontinence: Market Analysis
United States Market Size
Europe Market Size
Germany Market Size
France Market Size
United Kingdom Market Size
Spain Market Size
Italy Market Size
Japan Market Size
Market Drivers
Market Barriers
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
LIST OF TABLES
Table 1: 7 MM Market Size of Urinary Incontinence in USD Million (2013-2023)
Table 2: Prevalent Cases Urinary Incontinence in United States (2013-2023)
Table 3: Percentage Distribution of Urinary Incontinence by Sub Types in United States (2016)
Table 4: Prevalent Cases Urinary Incontinence in Germany (2013-2023)
Table 5: Percentage Distribution of Urinary Incontinence by Sub Types in Germany (2016)
Table 6: Prevalent Cases Urinary Incontinence in France (2013-2023)
Table 7: Percentage Distribution of Urinary Incontinence by Sub Types in France (2016)
Table 8: Prevalent Cases Urinary Incontinence in United Kingdom (2013-2023)
Table 9: Percentage Distribution of Urinary Incontinence by Sub Types in United Kingdom (2016)
Table 10: Prevalent Cases Urinary Incontinence in Spain (2013-2023)
Table 11: Percentage Distribution of Urinary Incontinence by Sub Types in Spain (2016)
Table 12: Prevalent Cases Urinary Incontinence in Italy (2013-2023)
Table 13: Percentage Distribution of Urinary Incontinence by Sub Types in Italy (2016)
Table 14: Prevalent Cases Urinary Incontinence in Japan (2013-2023)
Table 15: Percentage Distribution of Urinary Incontinence by Sub Types in Japan (2016)
Table 16: Marketed Drugs for Urinary Incontinence
Table 17: Emerging Therapies for Urinary Incontinence
Table 18: Total Urinary Incontinence, Distribution share (2016) as per the 7MM
Table 19: Total Urinary Incontinence, Distribution share (2023) as per the 7MM
Table 20: United States Market Size of Urinary Incontinence in USD, Million (2013-2023)
Table 21: Germany Market Size of Urinary Incontinence in USD, Million (2013-2023)
Table 22: France Market Size of Urinary Incontinence in USD, Million (2013-2023)
Table 23: United Kingdom Market Size of Urinary Incontinence in USD, Million (2013-2023)
Table 24: Spain Market Size of Urinary Incontinence in USD, Million (2013-2023)
Table 25: Italy Market Size of Urinary Incontinence in USD, Million (2013-2023)
Table 26: Japan Market Size of Urinary Incontinence in USD, Million (2013-2023)
Table 1: 7 MM Market Size of Urinary Incontinence in USD Million (2013-2023)
Table 2: Prevalent Cases Urinary Incontinence in United States (2013-2023)
Table 3: Percentage Distribution of Urinary Incontinence by Sub Types in United States (2016)
Table 4: Prevalent Cases Urinary Incontinence in Germany (2013-2023)
Table 5: Percentage Distribution of Urinary Incontinence by Sub Types in Germany (2016)
Table 6: Prevalent Cases Urinary Incontinence in France (2013-2023)
Table 7: Percentage Distribution of Urinary Incontinence by Sub Types in France (2016)
Table 8: Prevalent Cases Urinary Incontinence in United Kingdom (2013-2023)
Table 9: Percentage Distribution of Urinary Incontinence by Sub Types in United Kingdom (2016)
Table 10: Prevalent Cases Urinary Incontinence in Spain (2013-2023)
Table 11: Percentage Distribution of Urinary Incontinence by Sub Types in Spain (2016)
Table 12: Prevalent Cases Urinary Incontinence in Italy (2013-2023)
Table 13: Percentage Distribution of Urinary Incontinence by Sub Types in Italy (2016)
Table 14: Prevalent Cases Urinary Incontinence in Japan (2013-2023)
Table 15: Percentage Distribution of Urinary Incontinence by Sub Types in Japan (2016)
Table 16: Marketed Drugs for Urinary Incontinence
Table 17: Emerging Therapies for Urinary Incontinence
Table 18: Total Urinary Incontinence, Distribution share (2016) as per the 7MM
Table 19: Total Urinary Incontinence, Distribution share (2023) as per the 7MM
Table 20: United States Market Size of Urinary Incontinence in USD, Million (2013-2023)
Table 21: Germany Market Size of Urinary Incontinence in USD, Million (2013-2023)
Table 22: France Market Size of Urinary Incontinence in USD, Million (2013-2023)
Table 23: United Kingdom Market Size of Urinary Incontinence in USD, Million (2013-2023)
Table 24: Spain Market Size of Urinary Incontinence in USD, Million (2013-2023)
Table 25: Italy Market Size of Urinary Incontinence in USD, Million (2013-2023)
Table 26: Japan Market Size of Urinary Incontinence in USD, Million (2013-2023)
LIST OF FIGURES
Figure 1:Types of Urinary Incontinence
Figure 2:Risk Factors of Urinary Incontinence
Figure 3:Treatment of Urinary Incontinence
Figure 4: Prevalent Cases of Urinary Incontinence in United States (2013-2023)
Figure 5: Percentage Distribution ofUrinary Incontinence by Sub Types in United States (2016)
Figure 6: Prevalent Cases of Urinary Incontinence in Germany (2013-2023)
Figure 7: Percentage Distribution ofUrinary Incontinence by Sub Types in Germany (2016)
Figure 8: Prevalent Cases of Urinary Incontinence in France (2013-2023)
Figure 9: Percentage Distribution ofUrinary Incontinence by Sub Types in France (2016)
Figure 10: Prevalent Cases of Urinary Incontinence in United Kingdom (2013-2023)
Figure 11: Percentage Distribution ofUrinary Incontinence by Sub Types in United Kingdom (2016)
Figure 12: Prevalent Cases of Urinary Incontinence in Spain (2013-2023)
Figure 13: Percentage Distribution ofUrinary Incontinence by Sub Types in Spain (2016)
Figure 14: Prevalent Cases of Urinary Incontinence in Italy (2013-2023)
Figure 15: Percentage Distribution ofUrinary Incontinence by Sub Types in Italy (2016)
Figure 16: Prevalent Cases of Urinary Incontinence in Japan (2013-2023)
Figure 17: Percentage Distribution ofUrinary Incontinence by Sub Types in Japan (2016)
Figure 18:Treatment algorithm for Children with Urinary Incontinence
Figure 19:Treatment algorithm for Men with Urinary Incontinence
Figure 20:Treatment algorithm for Women with Urinary Incontinence
Figure 21: Total 7 Major Market Size of Urinary Incontinence in USD, Million (2016)
Figure 22: Total 7 Major Market Size of Urinary Incontinence in USD, Million (2023)
Figure 23: United States Market Size of Urinary Incontinence in USD, Million (2013-2023)
Figure 24: Germany Market Size of Urinary Incontinence in USD, Million (2013-2023)
Figure 25: France Market Size of Urinary Incontinence in USD, Million (2013-2023)
Figure 26: United Kingdom Market Size of Urinary Incontinence in USD, Million (2013-2023)
Figure 27: Spain Market Size of Urinary Incontinence in USD, Million (2013-2023)
Figure 28: Italy Market Size of Urinary Incontinence in USD, Million (2013-2023)
Figure 29: Japan Market Size of Urinary Incontinence in USD, Million (2013-2023)
Figure 30: Market Drivers for Urinary Incontinence
Figure 31: Market Barriers for Urinary Incontinence
Figure 1:Types of Urinary Incontinence
Figure 2:Risk Factors of Urinary Incontinence
Figure 3:Treatment of Urinary Incontinence
Figure 4: Prevalent Cases of Urinary Incontinence in United States (2013-2023)
Figure 5: Percentage Distribution ofUrinary Incontinence by Sub Types in United States (2016)
Figure 6: Prevalent Cases of Urinary Incontinence in Germany (2013-2023)
Figure 7: Percentage Distribution ofUrinary Incontinence by Sub Types in Germany (2016)
Figure 8: Prevalent Cases of Urinary Incontinence in France (2013-2023)
Figure 9: Percentage Distribution ofUrinary Incontinence by Sub Types in France (2016)
Figure 10: Prevalent Cases of Urinary Incontinence in United Kingdom (2013-2023)
Figure 11: Percentage Distribution ofUrinary Incontinence by Sub Types in United Kingdom (2016)
Figure 12: Prevalent Cases of Urinary Incontinence in Spain (2013-2023)
Figure 13: Percentage Distribution ofUrinary Incontinence by Sub Types in Spain (2016)
Figure 14: Prevalent Cases of Urinary Incontinence in Italy (2013-2023)
Figure 15: Percentage Distribution ofUrinary Incontinence by Sub Types in Italy (2016)
Figure 16: Prevalent Cases of Urinary Incontinence in Japan (2013-2023)
Figure 17: Percentage Distribution ofUrinary Incontinence by Sub Types in Japan (2016)
Figure 18:Treatment algorithm for Children with Urinary Incontinence
Figure 19:Treatment algorithm for Men with Urinary Incontinence
Figure 20:Treatment algorithm for Women with Urinary Incontinence
Figure 21: Total 7 Major Market Size of Urinary Incontinence in USD, Million (2016)
Figure 22: Total 7 Major Market Size of Urinary Incontinence in USD, Million (2023)
Figure 23: United States Market Size of Urinary Incontinence in USD, Million (2013-2023)
Figure 24: Germany Market Size of Urinary Incontinence in USD, Million (2013-2023)
Figure 25: France Market Size of Urinary Incontinence in USD, Million (2013-2023)
Figure 26: United Kingdom Market Size of Urinary Incontinence in USD, Million (2013-2023)
Figure 27: Spain Market Size of Urinary Incontinence in USD, Million (2013-2023)
Figure 28: Italy Market Size of Urinary Incontinence in USD, Million (2013-2023)
Figure 29: Japan Market Size of Urinary Incontinence in USD, Million (2013-2023)
Figure 30: Market Drivers for Urinary Incontinence
Figure 31: Market Barriers for Urinary Incontinence
